PLASMAKALLIKREINBINDENDE PROTEINE

European patent · EP2521568 · In force

Register entry

Publication number
EP2521568
Application number
EP11732145
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 6, 2011
Published
Nov 14, 2012
Granted
Jul 25, 2018
Protection ends at the latest
Jan 5, 2031
Next annual fee due
Jan 31, 2027
IPC classes
A61K 39/395 (2006.01)
C07K 16/18 (2006.01)
C07K 16/40 (2006.01)
Priority
US 292614 P 06.01.2010
PCT application
PCT/US2011/020377 06.01.2011
PCT publication
WO2011/085103 14.07.2011
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Lanadelumab

C02521568/01 · Medicine · Extended for paediatric use · Protection from Jan 6, 2031 to Dec 5, 2034

Authorisation 66912 (Swissmedic, Jun 6, 2019) · Authorisation 68178 (Swissmedic, Nov 5, 2020) · Authorisation 68178 (Swissmedic, Apr 11, 2024) · Authorisation 66912 (Swissmedic, Apr 6, 2018) · Authorisation 68178 (Swissmedic, Mar 30, 2020) · Authorisation 68178 (Swissmedic, Jan 25, 2023)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Dec 21, 2023

    Address changed

    Representative
    E. Blum & Co. AG, Patent- und Markenanwälte VSP, Vorderberg 11, 8044 Zürich → E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 21.12.2023

  5. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  6. Jul 15, 2021

    Agent entered

    Representative
    E. Blum & Co. AG, Patent- und Markenanwälte VSP, Vorderberg 11, 8044 Zürich

    Published in Swissreg on 15.07.2021

  7. May 29, 2021

    Transferred

    Owner
    Dyax Corp., 300 Shire Way, Lexington, MA 02421, USA → Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan

    Published in Swissreg on 29.05.2021

  8. Jul 25, 2018

    Granted

    Published in Swissreg on 25.07.2018

Parties

Holder

Takeda Pharmaceutical Company Limited

1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka, JP

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

SEXTON, Daniel, J.

Melrose, MA 02176, US

VISWANATHAN, Malini

Acton, MA 01720, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.